Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
158 hedge funds and large institutions have $500M invested in Momenta Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 61 increasing their positions, 40 reducing their positions, and 15 closing their positions.
167% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 15
53% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 40
19% more funds holding
Funds holding: 133 → 158 (+25)
16% more call options, than puts
Call options by funds: $13M | Put options by funds: $11.2M
2.65% more ownership
Funds ownership: 78.74% → 81.39% (+2.6%)
32% less capital invested
Capital invested by funds: $731M → $500M (-$230M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$51.3M |
| 2 |
Primecap Management
Pasadena,
California
|
+$11.1M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$9.94M |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.73M |
| 5 |
Renaissance Technologies
New York
|
+$7.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$64M |
| 2 |
DM
Deerfield Management
New York
|
-$20.1M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$10.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.07M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$6.77M |
MNTA Hedge Fund Activity: Q1 2014 in Review
158 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q1 2014, worth a combined $500M — down 32% from $731M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new MNTA positions and 15 closed out — a net gain of 25 holders — while 61 added to existing stakes and 40 trimmed.
The largest buyer was SAC Capital Advisors, opening a new position worth an estimated $51.3M. The largest seller was Visium Asset Management, exiting entirely with an estimated $64M sold.
- 158 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q1 2014, up from 133 in Q4 2013.
- Funds reported $500M of Momenta Pharmaceuticals, Inc. stock for Q1 2014, down 32% quarter-over-quarter.
- 40 funds opened new Momenta Pharmaceuticals, Inc. positions in Q1 2014 and 15 closed out, a net change of +25 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q1 2014 was SAC Capital Advisors, an estimated $51.3M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q1 2014 was Visium Asset Management, an estimated $64M sold.
Based on aggregated 13F filings for Q1 2014.